Author

M. G. Lewis

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 19 Microbiology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 24 Research Focus:host-pathogen & immune response· 23 Organism:non-human primate· 13 Assay:proteomics· 9 Organism:rat· 9 Research Focus:drug response / drug discovery· 8 Organism:mouse· 7 Research Focus:cell type annotation· 5

Frequent Co-Authors

H. Andersen· 17 shared L. Pessaint· 12 shared A. Cook· 10 shared M. Gagne· 7 shared A. Dodson· 6 shared A. Van Ry· 6 shared B. F. Haynes· 6 shared K. O. Saunders· 6 shared

Activity by Year

2020-2023 · peak 9/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

17 shared papersImmunology

H. Andersen

Mutual co-authors in cluster

Author profile →

24 papers

Recent·Most cited

Broadly neutralizing antibody induction by non-stabilized SARS-CoV-2 Spike mRNA vaccination in nonhuman primates

R. D. Malewana, V. Stalls, A. May, X. Lu, D. R. Martinez, A. Schafer, D. Li, M. Barr, L. L. Sutherland, E. Lee, R. Parks, W. E. Beck, A. Newman, K. W. Bock, M. Minai, , K. O. Saunders

Non-stabilized SARS-CoV-2 Spike mRNA vaccination in macaques induces B cell lineages targeting conserved epitopes on Omicron variants or cross-neutralizing epitopes on Sarbecoviruses.

bioRxiv · Dec 18, 2023 · PreprintImmunology

Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates

J. I. Moliva, S. F. Andrew, B. J. Flynn, D. A. Wagner, K. E. Foulds, M. Gagne, D. R. Flebbe, E. Lamb, S. Provost, J. Marquez, A. Mychalowych, C. Lorag, C. C. Honeycutt, M. R. Burnett, L. McCormick, , Nason

This study shows a gorilla adenovirus-based vaccine provides durable immunity against SARS-CoV-2 in both airways of non-human primates, with enhanced protection from aerosol delivery and prime-boost regimens.

bioRxiv · Nov 22, 2023 · PreprintImmunology

Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates

M. Gagne, B. J. Flynn, S. F. Andrew, D. R. Flebbe, A. Mychalowych, E. Lamb, M. E. Davis-Gardner, M. R. Burnett, L. A. Serebryannyy, B. C. Lin, L. Pessaint, J.-P. M. Todd, Z. E. Ziff, E. Maule, R. Carroll, , M Suthar

This study shows that mucosal adenoviral-vectored vaccines provide durable protection against XBB.1.16 infection in nonhuman primates, outperforming intramuscular boosting in reducing virus replication in both upper and lower airways.

bioRxiv · Nov 6, 2023 · PreprintImmunology

Germline-targeting chimpanzee SIV Envelopes induce V2-apex broadly neutralizing-like B cell precursors in a rhesus macaque infection model

R. Musharrafieh, Y. Safonova, G. Song, R. S. Roark, F.-H. Lee, S. Zhang, J. Hurtado, P. Yong, S. Wang, R. M. Russell, W. Ding, Y. Li, J. Rando, A. I. Murphy, E. Lindemuth, , R. Andrabi

This study shows that germline-targeting SCIVs can activate and expand B cells expressing V2-apex bnAb-like precursors in rhesus macaques.

bioRxiv · Sep 21, 2023 · PreprintImmunology

RBD-based high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways

M. Gagne, B. J. Flynn, C. C. Honeycutt, D. R. Flebbe, S. F. Andrew, S. J. Provost, L. McCormick, A. Van Ry, E. McCarthy, J.-P. M. Todd, S. Bao, I.-T. Teng, S. Marciano, Y. Rudich, C. Li, , D. C. Douek

RBD-62, a high-affinity ACE2 antagonist, limits SARS-CoV-2 replication in both upper and lower airways in rhesus macaques without blocking memory responses or causing anti-drug immunity.

bioRxiv · Jun 9, 2023 · PreprintImmunology

A germline-targeting chimpanzee SIV envelope glycoprotein elicits a new class of V2-apex directed cross-neutralizing antibodies

F. Bibollet-Ruche, R. M. Russell, W. Ding, W. Liu, Y. Li, K. Wagh, D. Wrapp, R. Habib, A. N. Skelly, R. S. Roark, S. Sherrill-Mix, S. Wang, J. Rando, E. Lindemuth, K. Cruickshank, , B. H. Hahn

This study identifies a new class of V2-directed cross-neutralizing antibodies targeting a cryptic epitope in occluded-open HIV and SIV Env trimers.

bioRxiv · Oct 18, 2022Immunology

Mosaic RBD nanoparticles protect against multiple sarbecovirus challenges in animal models

A. A. Cohen, N. A. van Doremalen, A. J. Greaney, H. Andersen, A. Sharma, T. N. Starr, J. R. Keeffe, C. Fan, J. E. Schulz, P. N. P. Gnanapragasam, L. M. Kakutani, A. P. West, G. Saturday, Y. E. Lee, H. Gao, , P. J. Bjorkman

This study designs mosaic RBD nanoparticles to elicit antibodies against conserved sarbecovirus epitopes, showing broader protection against SARS-CoV-2 variants and animal sarbecoviruses in animal models.

bioRxiv · Mar 25, 2022 · PreprintMicrobiology

Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques

A. Chandrashekar, J. Yu, K. McMahan, C. Jacob-Dolan, J. Liu, X. He, D. Hope, T. Anioke, J. Barrett, B. Chung, N. Hachmann, M. Lifton, J. Miller, O. Powers, M. Sciacca, , D. H. Barouch

This study evaluates vaccine efficacy against SARS-CoV-2 Omicron in macaques, finding that both humoral and cellular immune responses are necessary for virologic control.

bioRxiv · Feb 6, 2022Microbiology

Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine

D. Li, D. R. Martinez, A. Schäfer, H. Chen, M. Barr, L. L. Sutherland, E. Lee, R. Parks, D. Mielke, W. Edwards, A. Newman, K. W. Bock, M. Minai, B. M. Nagata, M. Gagne, , B. F. Haynes

This study shows a nanoparticle vaccine induces broad neutralizing antibodies against multiple SARS-CoV-2 variants and protects non-human primates and mice from viral challenges.

bioRxiv · Jan 26, 2022Immunology

Synthetic Multiantigen MVA Vaccine COH04S1 Protects Against SARS-CoV-2 in Syrian Hamsters and Non-Human Primates

F. Chiuppesi, V. H. Nguyen, Y. Park, H. Contreras, V. Karpinski, K. Faircloth, J. Nguyen, M. Kha, D. Johnson, J. Martinez, A. Iniguez, Q. Zhou, T. Kaltcheva, P. Frankel, S. Kar, , D. J. Diamond

This paper shows that the synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates through various vaccination routes and dose regimens.

npj Vaccines · Jan 21, 2022Peer-reviewedImmunology

Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters

K. McMahan, V. Giffin, L. Tostanoski, B. Chung, M. Siamatu, M. Suthar, P. Halfmann, Y. Kawaoka, C. Piedra-Mora, A. Martinot, S. Kar, H. Andersen, M. G. Lewis, D. H. Barouch

This study shows the SARS-CoV-2 Omicron variant causes less weight loss in hamsters than previous variants, suggesting reduced lower respiratory tract disease severity.

bioRxiv · Jan 2, 2022Microbiology

Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway

M. Gagne, K. S. Corbett, B. J. Flynn, K. E. Foulds, D. A. Wagner, S. F. Andrew, J.-P. M. Todd, C. C. Honeycutt, L. McCormick, S. T. Nurmukhambetova, M. E. Davis-Gardner, L. Pessaint, K. W. Bock, B. M. Nagata, M. Minai, , B. S. Graham

This study shows that mRNA-1273 vaccine protection against SARS-CoV-2 Delta in nonhuman primates persists for one year but is delayed and relies on anamnestic antibody responses in the lower airway.

bioRxiv · Oct 23, 2021 · PreprintImmunology

Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Proteinco-immunization in rhesus macaques

M. Rosati, M. Agarwal, X. Hu, S. Devasundaram, D. Stellas, B. Chowdhury, J. Bear, R. Burns, D. Donohue, L. Pessaint, H. Andersen, M. G. Lewis, E. Terpos, M. A. Dimopoulos, A. Wlodawer, , B. K. Felber

This study compares DNA and DNA+protein vaccines in rhesus macaques, finding that co-immunization with both induces stronger antibody responses and better control of SARS-CoV-2 infection.

PLOS Pathogens · Sep 22, 2021Peer-reviewedImmunology

Optimization of Non-Coding Regions Improves Protective Efficacy of an mRNA SARS-CoV-2 Vaccine in Nonhuman Primates

M. Gebre, S. Rauch, N. Roth, J. Yu, A. Chandrashekar, N. Mercado, X. He, J. Liu, K. McMahan, A. Martinot, T. Giffin, D. Hope, S. Patel, D. Sellers, O. Sanborn, , D. H. Barouch

This study compares two mRNA SARS-CoV-2 vaccines in nonhuman primates, showing that CV2CoV, with optimized non-coding regions, provides better immune responses and protection than CVnCoV.

bioRxiv · Aug 13, 2021 · PreprintImmunology

A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates

N. C. Dalvie, L. H. Tostanoski, S. A. Rodriguez-Aponte, K. Kaur, S. Bajoria, O. Kumru, A. J. Martinot, A. Chandrashekar, K. McMahan, N. B. Mercado, J. Yu, A. Chang, V. M. Giffin, F. Nampanya, S. Patel, , D. H. Barouch

This paper describes a protein subunit vaccine candidate produced in yeast that protects non-human primates against SARS-CoV-2, showing high neutralizing antibody titers and reduced viral loads after challenge.

bioRxiv · Jul 13, 2021 · PreprintImmunology

A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters

K. M. Wuertz, E. Barkei, W.-h. Chen, E. J. Martinez, I. E. Naouar, L. Jagodzinski, D. Paquin-Proulx, G. D. Gromowski, I. Swafford, A. Ganesh, M. Dong, X. Zeng, P. V. Thomas, R. S. Sankhala, A. Hajduczki, , Vasan

This study evaluates a SARS-CoV-2 spike ferritin nanoparticle vaccine's effectiveness against B.1.1.7 and B.1.351 variants in hamsters, showing protection against disease and viral replication.

bioRxiv · Jun 16, 2021 · PreprintImmunology

Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates

K. S. Corbett, A. Werner, S. O'Connell, M. Gagne, L. Lai, J. Moliva, B. Flynn, A. Choi, M. Koch, K. E. Foulds, S. Andrew, D. Flebbe, E. Lamb, S. T. Nurmukhambetova, S. Provost, , M. Suthar

This study evaluates mRNA-1273 vaccine efficacy against SARS-CoV-2 B.1.351 in nonhuman primates, finding that two doses significantly reduce viral replication in the airways.

bioRxiv · May 21, 2021 · PreprintImmunology

SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys

K. O. Saunders, E. Lee, R. Parks, D. R. Martinez, D. Li, H. Chen, R. J. Edwards, S. M. C. Gobeil, M. Barr, K. Mansouri, S. M. Alam, L. L. Sutherland, F. Cai, A. Sanzone, M. Berry, , B. F. Haynes

This study shows that SARS-CoV-2 vaccines induce neutralizing antibodies against SARS-CoV-1, SARS-CoV-2, and batCoVs in monkeys.

bioRxiv · Feb 17, 2021 · PreprintImmunology

Low-Dose Ad26.COV2.S Protection Against SARS-CoV-2 Challenge in Rhesus Macaques

X. He, A. Chandrashekar, R. C. Zahn, F. Wegmann, J. Yu, N. B. Mercado, K. McMahan, A. J. Martinot, C. Piedra-Mora, S. Beecy, S. Ducat, R. Chamanza, S. Rosendahl Huber, L. van der Fits, E. N. Borducchi, , D. H. Barouch

This study shows that low doses of Ad26.COV2.S vaccine protect rhesus macaques against SARS-CoV-2 challenge, with higher doses needed for upper respiratory tract protection.

bioRxiv · Jan 27, 2021Immunology

New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention and Cure

H. Li, S. Wang, F.-H. Lee, R. S. Roark, A. I. Murphy, J. Smith, C. Zhao, J. Rando, N. Chohan, Y. Ding, E. Kim, E. Lindemuth, K. J. Bar, I. Pandrea, C. Apetrei, , G. M. Shaw

This paper demonstrates that SHIVs with bulky aromatic amino acid substitutions at Env375 replicate efficiently in rhesus macaques and can be used for preclinical HIV vaccine testing.

bioRxiv · Jan 13, 2021Microbiology

Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates

K. O. Saunders, N. Pardi, R. Parks, S. Santra, Z. Mu, L. L. Sutherland, R. Scearce, M. Barr, A. Eaton, G. Hernandez, D. Goodman, M. J. Hogan, I. Tombacz, D. Gordon, R. W. Rountree, , B. F. Haynes

This study compares the immunogenicity of mRNA-LNP vaccines to protein vaccines in nonhuman primates, finding comparable or superior HIV-1 antibody responses.

bioRxiv · Dec 30, 2020Immunology

Recapitulation of HIV-1 Env-Antibody Coevolution in Macaques Leading to Neutralization Breadth

R. S. Roark, H. Li, W. B. Williams, H. Chug, R. D. Mason, J. Gorman, S. Wang, F.-H. Lee, J. Rando, M. Bonsignori, K.-K. Hwang, K. O. Saunders, K. Wiehe, M. A. Moody, P. T. Hraber, , C. A Schramm

Virus-antibody coevolution in rhesus macaques recapitulates developmental features of human antibodies.

bioRxiv · Aug 5, 2020Immunology

REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters

A. Baum, R. Copin, D. Ajithdoss, A. Zhou, K. Lanza, N. Negron, M. Ni, Y. Wei, G. S. Atwal, A. Oyejide, Y. Goez-Gazi, J. Dutton, E. Clemmons, H. M. Staples, C. Bartley, , C. A. Kyratsous

This study evaluates the efficacy of the REGN-COV2 antibody cocktail in preventing and treating SARS-CoV-2 infection in rhesus macaques and hamsters, showing reduced virus load and pathological effects.

bioRxiv · Aug 2, 2020Microbiology

Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model

A. Patel, J. Walters, E. L. Reuschel, K. Schultheis, E. Parzych, E. N. Gary, I. Maricic, M. Purwar, Z. Eblimit, S. N. Walker, D. Guimet, P. Bhojnagarwala, A. Doan, Z. Xu, D. Elwood, , K. E. Broderick

This study evaluates an intradermal DNA vaccine against SARS-CoV-2 in rhesus macaques, showing it induces immune responses and provides protection against viral challenge.

bioRxiv · Jul 28, 2020 · PreprintImmunology